Clinical Trial Update: RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS [Phase 2]

View source ↗

Summary

Phase 2 trial update for rapamycin targeting kidney angiomyolipomas associated with tuberous sclerosis; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Angiomyolipoma
• Tuberous Sclerosis Complex

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Nonmalignant Neoplasm, Tuberous Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2022-04-25